DUBLIN, Sept. 25, 2015 /CNW/ — Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that on September 24, 2015, it received notice of termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, from the U.S. Federal Trade Commission in connection with Endo’s previously announced acquisition of Par Pharmaceutical Holdings, Inc. As a result, all closing conditions relating to the Par acquisition have been satisfied and the parties will promptly proceed with the closing pursuant to the terms of the merger agreement.

About Endo International plc 

Endo International plc is a global specialty pharmaceutical company focused on improving patients’ lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that are based on current expectations of future events. If underlying assumptions prove inaccurate, or unknown risks or uncertainties materialize, results could vary from Endo’s expectations. Accordingly, you should not place undue reliance on any forward-looking statements, which apply only as of the date of this press release. Endo expressly disclaims any intent or obligation to update forward-looking statements except as required by law.